23andMe's 'Build-a-Baby' Patent Criticised
By BBC,
BBC News [Quotes CGS's Marcy Darnovsky]
| 10. 03. 2013
A US patent for a database that uses DNA testing to tell prospective parents which traits their future offspring may inherit has been criticised by experts.
23andMe says its Family Traits Inheritor Calculator can predict the risk of inheriting specific diseases as well as details such as height, weight, eye colour and even personality.
Couples send the firm a saliva sample to see what their babies might be like.
But critics have called the project "ethically and socially treacherous".
Designer babies
The patent suggests the database could also be used by fertility clinics to find appropriate donors.
But the Mountain View, California-based firm was quick to say this was no longer part of its plan.
"At the time 23andMe filed the patent, there was consideration that the technology could have potential applications for fertility clinics so language specific to the fertility treatment process was included in the patent," it said in a blog post.
"The company never pursued the concepts discussed in the patent beyond our Family Traits Inheritance Calculator, nor do we have any plans to do...
Related Articles
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...
By Charles Pulliam-Moore, The Verge | 03.21.2026
Like many people, director Valerie Veatch was intrigued when OpenAI first released its Sora text-to-video generative AI model to the public in 2024. Though she didn’t fully understand the technology, she was curious about what it could do, and she...
By Emily Mullin, Wired | 03.23.2026
As the Trump administration phases out the use of animal experimentation across the federal government, a biotech startup has a bold idea for an alternative to animal testing: nonsentient “organ sacks.”
Bay Area-based R3 Bio has been quietly pitching the...